GET DAILY SIGNALSInMode Ltd. (INMD): A Closer Look at the Medical Aesthetics Company
Key Takeaways
- INMD is the Nasdaq-listed ticker for InMode Ltd., an Israel-based medical device maker specializing in energy-based aesthetic and medical treatments.
- The company's products use proprietary radio frequency (RF) technology for minimally invasive, non-invasive, and hands-free procedures across plastic surgery, dermatology, gynecology, and ophthalmology.
- InMode operates a "razor-and-blade" business model, generating revenue from both capital equipment sales and recurring consumables and service.
- The company sells primarily through a direct sales force, with a growing international footprint alongside its historically large U.S. business.
- InMode is known for high gross margins and a strong cash position, but operates in a discretionary, economically sensitive market.
An Overview of InMode
InMode Ltd. is a global medical technology company that designs, develops, manufactures, and markets energy-based devices for aesthetic and medical treatments. Traded on the Nasdaq Global Select Market under the ticker INMD, the company has become one of the more recognizable names in the medical aesthetics industry. Investors follow InMode for its proprietary radio frequency (RF) technology, its direct-sales distribution model, and a financial profile characterized by unusually high gross margins relative to many medical device peers. From what I see, these elements set it apart in a competitive space.
The Company's Roots and Technology
InMode was incorporated on January 2, 2008, and is headquartered in Yokne'am, Israel. The company was formerly known as Invasix Ltd. before changing its name to InMode Ltd. in November 2017. It has traded on Nasdaq since August 2019. The company was co-founded by Moshe Mizrahy, who serves as Chief Executive Officer, and Dr. Michael Kreindel, its Chief Technology Officer.
InMode's core technology is built on proprietary radio frequency assisted lipolysis and deep subdermal fractional RF technology. Radio frequency energy is used to heat tissue beneath the skin, enabling procedures such as body contouring, skin tightening, and facial rejuvenation. The company's product portfolio is organized around three broad categories:
- Minimally invasive platforms — used for liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation.
- Non-invasive platforms — targeting procedures such as permanent hair reduction, wrinkle reduction, and treatment of pigmented lesions.
- Hands-free platforms — focused on skin tightening, fat reduction, and muscle stimulation.
Well-known product platforms in the InMode portfolio include BodyTite, Morpheus8, Votiva, Contoura, EvolveX, Evoke, and EmpowerRF. These devices are used across plastic surgery, dermatology, gynecology, otolaryngology (ENT), and ophthalmology practices. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue Model and Distribution Approach
InMode's business model resembles a classic razor-and-blade approach. The company sells capital equipment — its RF-based platforms — to physicians, clinics, and medical spas, and then generates recurring revenue from single-use consumables, extended warranties, and service. This structure means that a portion of revenue is tied to the installed base of devices, providing a degree of recurring, high-margin income beyond one-time equipment sales.
Historically, capital equipment has represented the large majority of InMode's revenue, with consumables and service contributing a smaller but recurring share. The company's financial profile is notable for gross margins that have frequently approached 80%, reflecting the value of its proprietary technology and the relatively low cost of the consumables it sells.
Geographically, InMode has long relied on the United States as its largest market, but it has steadily expanded its international presence through wholly owned subsidiaries across North America, Europe, Asia, and Latin America, as well as distributor partnerships in other regions. The company sells most of its products through a direct sales force, a strategy that allows it to capture more of the value of each sale and maintain closer relationships with physician customers.
What Draws Investors to INMD
Several factors draw investor attention to InMode. First, its proprietary RF technology and a broad product portfolio position it as a meaningful competitor in the growing medical aesthetics market, which spans both medical practices and consumer-facing aesthetics. Second, its razor-and-blade revenue model creates a recurring stream of consumables sales that scales with the installed base of devices.
InMode also stands out for its financial characteristics. The company has maintained high gross margins, a strong balance sheet with substantial cash, and a history of returning capital to shareholders through share repurchases. Its ongoing investment in research and development — including new platform launches and expanded indications across ophthalmology and ENT — represents a potential long-term growth driver as it seeks to address new medical specialties.
Risks and Important Considerations
InMode operates in a discretionary, economically sensitive market. Demand for aesthetic procedures can weaken when consumer confidence declines or when financing for equipment purchases becomes more expensive, which can pressure both capital equipment sales and procedure volumes. The company's U.S. business in particular has shown sensitivity to macroeconomic conditions and shifts in the aesthetic industry.
Other considerations include intense competition in the medical aesthetics space, regulatory requirements across many countries, and the company's exposure to geopolitical conditions in Israel, where its operations are headquartered. Changes in tariffs and supply-chain conditions can also affect margins. Finally, because a significant share of revenue comes from capital equipment, results can fluctuate from quarter to quarter depending on the timing of purchases by physicians and clinics.
Exploring Opportunities with Tickeron's AI Screener
When I want to evaluate stocks like INMD against peers or spot patterns in the medical device space, Tickeron's AI Screener has been a useful resource. It lets users apply technical indicators, fundamentals, AI signals, and custom filters to narrow down ideas efficiently. In my view, incorporating tools like this supports a more structured way to review opportunities without replacing individual judgment.
Conclusion
InMode Ltd. has established itself as a distinctive player in medical aesthetics by combining proprietary radio frequency technology with a direct-sales model and a razor-and-blade revenue structure. Its broad product portfolio across multiple medical specialties, high-margin financial profile, and expanding international footprint make it a company worth understanding for investors interested in healthcare and medical technology. At the same time, its exposure to discretionary consumer spending and a competitive, regulated industry underscores the importance of evaluating both the opportunities and the risks that define this business.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INMD's RSI Indicator ascends from oversold territory
The RSI Indicator for INMD moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 29 of the 35 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in 164 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In 73 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for INMD turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 28 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
The 50-day moving average for INMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for INMD entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.219) is normal, around the industry mean (4.142). P/E Ratio (10.750) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.452) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally-invasive aesthetic medical products
Industry MedicalNursingServices
Advertisement